Please enable JavaScript or talk to your local administrator to get JavaScript enabled.


[Novel therapeutic strategy for canine urothelial carcinoma: cancer elimination by anti-inflammation with BRAF inhibitor]

Original in Japanese: Novel therapeutic strategy for canine urothelial carcinoma: cancer elimination by anti-inflammation with BRAF inhibitor

Funder: Japan Society for the Promotion of Science

Funding period
JPY 4.3 M
USD 39 K
Funding amount
[Canine urothelial cancer (UC) is the only cancer that responds to non-steroidal anti-inflammatory drugs, but lacks resistance development and other treatment options and may be a new treatment to improve prognosis. Established is required. Applicants have shown that UC produces large amounts of prostaglandin E2, which is involved in the promotion of inflammation, and that BRAF gene mutations, which are frequently found in UC, control it. In this study, we believe that targeting this mutation may control the inflammatory environment of UC, and aim to establish a new cancer treatment method using BRAF inhibitors. At the same time, by analyzing the gene expression of UC cells in urine, we would like to clarify the effect of BRAF inhibition on the inflammatory environment in vivo.]
Original in Japanese
Similar projects All >
Sorted by: Start Date
Project list item
Effect of APOBEC3 on Bladder Cancer Biology and Response to Immunotherapy

National Cancer Institute to ANDREW TRUONG

USD 45,016
2020 - 2023
Project list item
Analysis of the antineoplastic action of Class I HDAC inhibitors to define new combination therapies for urothelial carcinoma

German Research Foundation to Günter Niegisch, Michèle Janine Hoffmann

2020 -
Project list item
Unravelling Mechanisms of Resistance to Checkpoint Inhibition in Canine Urothelial Carcinoma

V Foundation for Cancer Research to Nicola J. Mason

USD 500,000
2019 - 2021
Project list item
Engineering Smart Solutions for Disorders of the Bladder Urothelium

Engineering and Physical Sciences Research Council

2019 - 2023
Project list item
[Clinicopathological and molecular analyses of precursor lesions of urothelial carcinoma] - Original in Japanese

Japan Society for the Promotion of Science to Shin-ichi MURATA, 生笛 松崎

USD 39,492
2019 - 2022



    1112 Oncology and Carcinogenesis

  • RCDC


  • RCDC


  • RCDC





    5.1 Pharmaceuticals

  • Health Research Areas


  • Broad Research Areas

    Clinical Medicine and Science